Wintermute Biomedical Inc
June 16, 2025
Company Presentation
Infectious Disease and Vaccines
Wintermute Biomedical Inc (WBI) is a antimicrobial development company with a focus on topical agents for the treatment of viruses, multi drug resistant bacteria, and fungus. WBI is currently completing a phase Ib double blind placebo with its first-in-class topical antiviral, Solexan, for the direct treatment of shingles lesions. This trial is being conducted at 5 trial sites in Australia and New Zealand and is projected to complete recruitment in May 2025 (26 out of 30 currently recruited). WBI technology is based on an ammonium carboxylate salt technology that utilizes fatty acids and amino acids that polymerize into antimicrobial micelles between 20-200nm. This technology means the antimicrobial is water soluble and relatively non-toxic. WBI is working to find partners and funders for a phase II/III pivotal study leading to registration.
Company HQ City:
Corvallis
Company HQ State:
MT
Company HQ Country:
United States
Year Founded:
2012
Lead Product in Development:
Solexan, first-in-class topical antiviral for shingles treatment.
CEO
Dr. Thomas Rau
Development Phase of Lead Product
Phase I
Number of Unlicensed Products Looking for Licensing
4
When you expect your next catalyst update?
Clinical trial completion and clinical data analysis and release.
What is your next catalyst (value inflection) update?
July/August 2025
Primary Speaker
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}